Gene Biotherapeutics Inc. is a clinical stage biotechnology company. The Company is focused on pre-clinical, clinical and commercialization of angiogenic gene therapy biotherapeutics for primarily for the treatment of cardiovascular disease. The Company’s technology platform is designed to biologically activate the human body’s innate angiogenic healing process to stimulate the growth of microvascular networks for patients with ischemic cardiovascular, cerebral, and other medical conditions and diseases, as well as for tissue engineering applications. Its lead product candidate Generx (Ad5FGF-4) is an angiogenic gene therapy product candidate designed for medical revascularization for the treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. Generx has been cleared Phase III clinical study, the AFFIRM study.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)